»Glycotest™ Announces Grant of Japanese Patent
05 Oct, 2017

New York, NY— October 05, 2017—Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted.

Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and increase survival for the growing population at risk from serious liver diseases. Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry.

The Japanese patent announced today is the latest in an expanding portfolio that now includes 10 granted or allowed patents protecting multiple aspects of Glycotest’s proprietary liver disease diagnostic platform, including over 50 unique glycoprotein biomarkers and the assay technology needed to measure them. These patents have been licensed exclusively and on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation, both in the Philadelphia area. Further expansion and strengthening of the Company’s intellectual property position is expected from applications pending in commercially important US and international jurisdictions.

Glycotest’s Chief Executive Officer Lawrence Cohen said, “This latest Japanese patent provides an important layer of protection for Glycotest’s lead HCC Panel test for early-stage liver cancer in a part of the world significantly impacted by this life-threatening disease. Glycotest is commercializing the HCC Panel test to provide physicians with a greatly needed to tool to identify patients eligible for life-saving curative therapy.”

About Glycotest, Inc.

Glycotest is a private liver disease diagnostics company commercializing novel clinical laboratory testing services for patients at risk for liver cancers and fibrosis-cirrhosis. The Company was founded in 2012 on proprietary technology that originated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine. Learn more at